Skip to main content
Article
Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19
bioRxiv
  • Dorien Feyaerts, Stanford University School of Medicine
  • Julien Hedou, Stanford University School of Medicine
  • Joshua Gillard, Radboud Institute for Molecular Life Sciences
  • Han Chen, Stanford University School of Medicine
  • Eileen S. Tsai, Stanford University School of Medicine
  • Laura S. Peterson, Stanford University School of Medicine
  • Kazuo Ando, Stanford University School of Medicine
  • Monali Manohar, Stanford University School of Medicine
  • Evan Do, Stanford University School of Medicine
  • Gopal K.R. Chinthrajah, Stanford University School of Medicine
  • Christopher M. Warren, Stanford University School of Medicine
  • Rich Wittman, Stanford University School of Medicine
  • Justin G. Meyeroqitz, Stanford University School of Medicine
  • Edward A. Ganio, Stanford University School of Medicine
  • Ina A. Stelzer, Stanford University School of Medicine
  • Xiaoyuan Han, University of the Pacific
  • Franck Verdonk, Stanford University School of Medicine
  • Dyani K. Gaudilliere, Stanford University School of Medicine
  • Nilanjan Mukherjee, Stanford University School of Medicine
  • Amy S. Tsai, Stanford University School of Medicine
  • Kristen K. Rumer, Stanford University School of Medicine
  • Sizun Jiang, Stanford University School of Medicine
  • Sergio Ivan Valdes Ferrer, Instituto Nacional de Ciencias Médicas y Nutrición
  • J. Daniel Kelly, University of California, San Francisco
  • David Furman, Buck Institute for Research on Aging
  • Nima Aghaeepour, Stanford University School of Medicine
  • Martin S. Angst, Stanford University School of Medicine
  • Scott D. Boyd, Stanford University School of Medicine
  • Benjamin A. Pinsky, Stanford University School of Medicine
  • Garry P. Nolan, Stanford University School of Medicine
  • Kari C. Nadeau, Stanford University
  • Brice Gaudilliere, Stanford University
  • David R. McIlwain, Stanford University School of Medicine
Department
Biomedical Sciences
Document Type
Article
DOI
10.1101/2021.02.09.430269
Publication Date
2-12-2021
Abstract

The biological determinants of the wide spectrum of COVID-19 clinical manifestations are not fully understood. Here, over 1400 plasma proteins and 2600 single-cell immune features comprising cell phenotype, basal signaling activity, and signaling responses to inflammatory ligands were assessed in peripheral blood from patients with mild, moderate, and severe COVID-19, at the time of diagnosis. Using an integrated computational approach to analyze the combined plasma and single-cell proteomic data, we identified and independently validated a multivariate model classifying COVID-19 severity (multi-class AUCtraining = 0.799, p-value = 4.2e-6; multi-class AUCvalidation = 0.773, p-value = 7.7e-6). Features of this high-dimensional model recapitulated recent COVID-19 related observations of immune perturbations, and revealed novel biological signatures of severity, including the mobilization of elements of the renin-angiotensin system and primary hemostasis, as well as dysregulation of JAK/STAT, MAPK/mTOR, and NF-κB immune signaling networks. These results provide a set of early determinants of COVID-19 severity that may point to therapeutic targets for the prevention of COVID-19 progression.

Comments

This is an unpublished pre-print that has not undergone peer review. It should not be considered conclusive, used to inform clinical practice, or referenced by the media as validated information.

Creative Commons License
Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International
Citation Information
Dorien Feyaerts, Julien Hedou, Joshua Gillard, Han Chen, et al.. "Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19" bioRxiv (2021)
Available at: http://works.bepress.com/xiaoyuan-han/54/